ACAD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 28.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $2,331,351.11

ACADIA Pharmaceuticals Insider Trading History Chart

ACADIA Pharmaceuticals Share Price & Price History

^$16.61

▼ -0.46 (-2.69%)

As of 03/31/2025 05:00 PM ET

Days: 30 | 90 | 365

ACADIA Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/26/2025	James Kihara	Insider	Sell	1,095	$17.05	$18,669.75	21,275
3/26/2025	Mark C. Schneyer	EVP	Sell	3,171	$17.05	$54,065.55	56,889
3/5/2025	Elizabeth A Garofalo	Director	Sell	4,919	$18.23	$89,673.37	17,595
2/24/2025	James Kihara	Insider	Sell	475	$19.96	$9,481.00	20,228
2/24/2025	Mark C. Schneyer	CFO	Sell	773	$19.96	$15,429.08	53,882
11/19/2024	Brendan Teehan	COO	Sell	10,329	$16.81	$173,630.49	62,105
11/19/2024	James Kihara	Insider	Sell	4,073	$16.81	$68,467.13	19,863
11/19/2024	Mark C. Schneyer	CFO	Sell	10,259	$16.81	$172,453.79	53,302
8/19/2024	Brendan Teehan	COO	Sell	9,534	$15.28	$145,679.52	52,177
8/19/2024	Mark C. Schneyer	CFO	Sell	9,733	$15.28	$148,720.24	43,735
8/19/2024	Stephen R. Davis	CEO	Sell	31,747	$15.28	$485,094.16	186,555
6/10/2024	Mark C. Schneyer	CFO	Sell	975	$14.79	$14,420.25	34,564
5/2/2024	Brendan Teehan	COO	Sell	3,477	$16.94	$58,900.38	42,133
5/2/2024	James Kihara	Insider	Sell	1,326	$16.94	$22,462.44	14,370
5/2/2024	Mark C. Schneyer	CFO	Sell	3,503	$16.94	$59,340.82	32,053
5/2/2024	Stephen R. Davis	CEO	Sell	11,427	$16.94	$193,573.38	155,231
4/8/2024	Brendan Teehan	COO	Sell	2,568	$17.87	$45,890.16	38,796
4/8/2024	James Kihara	Insider	Sell	1,790	$17.87	$31,987.30	13,100
4/8/2024	Mark C. Schneyer	CFO	Sell	2,716	$17.87	$48,534.92	28,742
4/8/2024	Stephen R. Davis	CEO	Sell	26,574	$17.87	$474,877.38	144,267
3/27/2024	Brendan Teehan	COO	Sell	5,140	$17.90	$92,006.00	36,340
3/27/2024	Mark C. Schneyer	CFO	Sell	5,434	$17.90	$97,268.60	26,183
3/27/2024	Stephen R. Davis	CEO	Sell	17,714	$17.90	$317,080.60	118,842
2/26/2024	Brendan Teehan	COO	Sell	624	$24.67	$15,394.08	31,432
2/26/2024	James Kihara	Insider	Sell	474	$24.67	$11,693.58	11,391
2/26/2024	Mark C. Schneyer	CFO	Sell	772	$24.67	$19,045.24	21,067
2/26/2024	Stephen R. Davis	CEO	Sell	5,577	$24.67	$137,584.59	101,890
1/8/2024	Austin D Kim	EVP	Sell	590	$29.96	$17,676.40	46,901
1/8/2024	Brendan Teehan	COO	Sell	731	$29.96	$21,900.76	30,949
1/8/2024	Stephen R. Davis	CEO	Sell	3,732	$29.96	$111,810.72	96,521
12/15/2023	James Kihara	Insider	Sell	2,000	$28.30	$56,600.00	11,025
11/20/2023	Brendan Teehan	COO	Sell	4,960	$22.64	$112,294.40	30,393
11/20/2023	James Kihara	Insider	Sell	1,985	$22.64	$44,940.40	13,025
11/20/2023	Mark C. Schneyer	CFO	Sell	5,108	$22.64	$115,645.12	20,486
10/6/2023	Austin D Kim	EVP	Sell	16,369	$21.96	$359,463.24	45,857
10/6/2023	Stephen R. Davis	CEO	Sell	51,563	$21.96	$1,132,323.48	89,131
9/15/2023	James Kihara	Insider	Sell	2,000	$25.88	$51,760.00	10,778
8/21/2023	Mark C. Schneyer	CFO	Sell	10,000	$29.00	$290,000.00	15,682
7/14/2023	Stephen R. Davis	CEO	Sell	100,000	$30.04	$3,004,000.00	36,695
7/11/2023	Stephen R. Davis	CEO	Sell	16,498	$25.00	$412,450.00	91,799
6/15/2023	James Kihara	Insider	Sell	2,000	$24.15	$48,300.00	9,144
6/12/2023	Laura Brege	Director	Sell	4,500	$24.87	$111,915.00	13,502
6/8/2023	Mark C. Schneyer	CFO	Sell	974	$25.02	$24,369.48	22,824
5/23/2023	Bros. Advisors Lp Baker	Director	Buy	209,053	$25.41	$5,312,036.73	38,811,515
5/17/2023	Brendan Teehan	COO	Sell	14,869	$22.50	$334,552.50	24,356
5/17/2023	James Kihara	Insider	Sell	5,947	$22.50	$133,807.50	11,144
5/17/2023	Mark C. Schneyer	CFO	Sell	15,310	$22.50	$344,475.00	21,905
5/1/2023	Austin D Kim	EVP	Sell	917	$21.18	$19,422.06	25,513
5/1/2023	Brendan Teehan	COO	Sell	548	$21.18	$11,606.64	9,487
5/1/2023	Stephen R. Davis	CEO	Sell	7,806	$21.18	$165,331.08	108,297
4/10/2023	James Kihara	Insider	Sell	523	$18.14	$9,487.22	5,197
4/6/2023	Austin D Kim	EVP	Sell	1,456	$18.16	$26,440.96	23,425
4/6/2023	Brendan Teehan	COO	Sell	1,751	$18.16	$31,798.16	8,468
4/6/2023	James Kihara	Insider	Sell	701	$18.16	$12,730.16	4,231
4/6/2023	Mark C. Schneyer	CFO	Sell	1,916	$18.16	$34,794.56	7,477
4/6/2023	Stephen R. Davis	CEO	Sell	8,582	$18.16	$155,849.12	100,478
2/24/2023	Austin D Kim	EVP	Sell	803	$18.78	$15,080.34	20,108
2/24/2023	Brendan Teehan	COO	Sell	461	$18.78	$8,657.58	5,195
2/24/2023	James Kihara	Insider	Sell	350	$18.78	$6,573.00	2,923
2/24/2023	Mark C. Schneyer	CFO	Sell	577	$18.78	$10,836.06	4,118
2/24/2023	Stephen R. Davis	CEO	Sell	3,851	$18.78	$72,321.78	91,727
1/12/2023	Laura Brege	Director	Sell	12,500	$18.25	$228,125.00
1/9/2023	Austin D Kim	EVP	Sell	589	$17.13	$10,089.57	18,697
1/9/2023	Brendan Teehan	COO	Sell	532	$17.13	$9,113.16	4,549
1/9/2023	Stephen R. Davis	CEO	Sell	3,904	$17.13	$66,875.52	84,633
11/21/2022	Srdjan R Stankovic	President	Sell	1,847	$15.07	$27,834.29	61,234
10/15/2022	Srdjan R Stankovic	President	Sell	1,326	$15.81	$20,964.06	56,831
10/15/2022	Stephen R. Davis	CEO	Sell	2,804	$15.81	$44,331.24	79,009
6/9/2022	Mark C. Schneyer	CFO	Sell	653	$17.91	$11,695.23	3,342
5/2/2022	Austin D Kim	EVP	Sell	894	$18.18	$16,252.92	16,742
5/2/2022	Brendan Teehan	COO	Sell	552	$18.18	$10,035.36	3,437
5/2/2022	Srdjan R Stankovic	President	Sell	2,865	$18.18	$52,085.70	55,188
5/2/2022	Stephen R. Davis	CEO	Sell	5,483	$18.18	$99,680.94	75,875
4/8/2022	James Kihara	insider	Sell	1,025	$27.05	$27,726.25	2,433

See Full Table

SEC Filings (Institutional Ownership Changes) for ACADIA Pharmaceuticals (NASDAQ:ACAD)

96.71% of ACADIA Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

ACADIA Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/24/2025	Wellington Management Group LLP	55,712	$1.02M	0.0%	-11.0%	0.033%
3/5/2025	Phocas Financial Corp.	107,811	$1.98M	0.3%	+79.0%	0.065%
2/27/2025	Jefferies Financial Group Inc.	114,766	$2.11M	0.0%	N/A	0.069%
2/20/2025	Mackenzie Financial Corp	51,065	$0.94M	0.0%	+180.1%	0.031%
2/19/2025	GF Fund Management CO. LTD.	3,494	$64K	0.0%	N/A	0.002%
2/19/2025	CTC Alternative Strategies Ltd.	55,133	$1.01M	1.2%	N/A	0.033%
2/18/2025	Neo Ivy Capital Management	57,504	$1.06M	0.2%	+1,551.5%	0.035%
2/18/2025	Alpine Global Management LLC	55,566	$1.02M	0.2%	N/A	0.033%
2/18/2025	JT Stratford LLC	15,170	$0.28M	0.0%	N/A	0.009%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	219,125	$4.02M	0.0%	+15.5%	0.132%
2/17/2025	Voloridge Investment Management LLC	725,508	$13.31M	0.0%	-44.6%	0.436%
2/17/2025	Woodline Partners LP	26,765	$0.49M	0.0%	N/A	0.016%
2/17/2025	Virtus Fund Advisers LLC	2,135	$39K	0.1%	N/A	0.001%
2/17/2025	Virtus Investment Advisers Inc.	39,370	$0.72M	0.6%	N/A	0.024%
2/17/2025	Squarepoint Ops LLC	185,313	$3.40M	0.0%	-67.7%	0.111%
2/17/2025	Two Sigma Advisers LP	1,263,200	$23.18M	0.1%	+160.8%	0.759%
2/17/2025	Two Sigma Investments LP	1,243,442	$22.82M	0.0%	+12.0%	0.747%
2/17/2025	State of Wyoming	10,406	$0.19M	0.0%	+70.8%	0.006%
2/17/2025	Stonepine Capital Management LLC	220,000	$4.04M	3.3%	+11.7%	0.132%
2/17/2025	Tema Etfs LLC	10,596	$0.19M	0.1%	N/A	0.006%
2/17/2025	Shay Capital LLC	37,263	$0.68M	0.1%	+102.2%	0.022%
2/17/2025	Sherbrooke Park Advisers LLC	22,638	$0.42M	0.1%	+22.6%	0.014%
2/17/2025	Sphera Funds Management LTD.	288,539	$5.30M	1.0%	+14.3%	0.173%
2/17/2025	RTW Investments LP	8,705,501	$159.75M	2.4%	-36.5%	5.232%
2/17/2025	Rafferty Asset Management LLC	150,234	$2.76M	0.0%	-47.4%	0.090%
2/17/2025	Point72 Asia Singapore Pte. Ltd.	16,974	$0.31M	0.1%	N/A	0.010%
2/17/2025	Point72 Asset Management L.P.	2,230,815	$40.94M	0.1%	N/A	1.341%
2/17/2025	Point72 Europe London LLP	173,155	$3.18M	0.2%	N/A	0.104%
2/17/2025	Point72 Hong Kong Ltd	24,054	$0.44M	0.0%	N/A	0.014%
2/17/2025	ProShare Advisors LLC	41,580	$0.76M	0.0%	+28.3%	0.025%
2/17/2025	Quantedge Capital Pte Ltd	76,900	$1.41M	0.5%	N/A	0.046%
2/17/2025	Man Group plc	1,221,022	$22.41M	0.1%	-4.3%	0.734%
2/17/2025	Nuveen Asset Management LLC	1,347,093	$24.72M	0.0%	-1.2%	0.810%
2/17/2025	Millennium Management LLC	1,118,361	$20.52M	0.0%	-45.5%	0.672%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	83,649	$1.53M	0.0%	-3.7%	0.050%
2/17/2025	Lazard Asset Management LLC	150,928	$2.77M	0.0%	+55.5%	0.091%
2/17/2025	Laurion Capital Management LP	98,896	$1.82M	0.0%	N/A	0.059%
2/17/2025	Jacobs Levy Equity Management Inc.	1,138,704	$20.90M	0.1%	-6.0%	0.684%
2/17/2025	Jefferies Financial Group Inc.	114,766	$2.11M	0.0%	N/A	0.069%
2/17/2025	Hudson Bay Capital Management LP	265,000	$4.86M	0.0%	-29.3%	0.159%
2/17/2025	Gotham Asset Management LLC	69,966	$1.28M	0.0%	+95.8%	0.042%
2/17/2025	Graham Capital Management L.P.	61,777	$1.13M	0.0%	N/A	0.037%
2/17/2025	Fred Alger Management LLC	2,714,929	$49.82M	0.2%	-14.8%	1.632%
2/17/2025	Deutsche Bank AG	1,042,447	$19.13M	0.0%	-33.9%	0.627%
2/17/2025	D. E. Shaw & Co. Inc.	3,241,406	$59.48M	0.0%	-7.5%	1.948%
2/17/2025	Cubist Systematic Strategies LLC	634,520	$11.64M	0.1%	N/A	0.381%
2/17/2025	Brevan Howard Capital Management LP	56,749	$1.04M	0.0%	+321.0%	0.034%
2/17/2025	Bridgefront Capital LLC	18,377	$0.34M	0.1%	+17.5%	0.011%
2/17/2025	Balyasny Asset Management L.P.	396,922	$7.28M	0.0%	-64.7%	0.239%
2/17/2025	Bank of America Corp DE	680,853	$12.49M	0.0%	+41.4%	0.409%
2/17/2025	BNP Paribas Financial Markets	288,471	$5.29M	0.0%	+29.0%	0.173%
2/17/2025	Ameriprise Financial Inc.	884,870	$16.24M	0.0%	+15.8%	0.532%
2/17/2025	Algert Global LLC	485,904	$8.92M	0.2%	-11.6%	0.292%
2/14/2025	PDT Partners LLC	12,326	$0.23M	0.0%	-6.7%	0.007%
2/14/2025	Schonfeld Strategic Advisors LLC	69,169	$1.27M	0.0%	+77.6%	0.042%
2/14/2025	Emerald Mutual Fund Advisers Trust	500,391	$9.18M	0.6%	-12.9%	0.301%
2/14/2025	Northern Trust Corp	1,232,366	$22.61M	0.0%	+9.4%	0.741%
2/14/2025	The Manufacturers Life Insurance Company	628,016	$11.52M	0.0%	+52.0%	0.377%
2/14/2025	Tudor Investment Corp ET AL	71,680	$1.32M	0.0%	-23.3%	0.043%
2/14/2025	Aquatic Capital Management LLC	50,269	$0.92M	0.0%	N/A	0.030%
2/14/2025	Oxford Asset Management LLP	11,925	$0.22M	0.1%	N/A	0.007%
2/14/2025	Birchview Capital LP	338,400	$6.21M	5.0%	-15.5%	0.203%
2/14/2025	Virtus ETF Advisers LLC	20,258	$0.37M	0.2%	-7.2%	0.012%
2/14/2025	Nebula Research & Development LLC	50,037	$0.92M	0.1%	+38.2%	0.030%
2/14/2025	Voya Investment Management LLC	36,167	$0.66M	0.0%	-22.8%	0.022%
2/14/2025	Price T Rowe Associates Inc. MD	621,010	$11.40M	0.0%	-5.9%	0.373%
2/14/2025	Dark Forest Capital Management LP	45,319	$0.83M	0.1%	-39.2%	0.027%
2/14/2025	Alpine Global Management LLC	55,566	$1.02M	0.2%	N/A	0.033%
2/14/2025	Hsbc Holdings PLC	69,021	$1.28M	0.0%	+6.2%	0.041%
2/14/2025	Tower Research Capital LLC TRC	13,118	$0.24M	0.0%	+202.3%	0.008%
2/14/2025	MetLife Investment Management LLC	73,048	$1.34M	0.0%	+3.8%	0.044%
2/14/2025	Dimensional Fund Advisors LP	1,086,840	$19.93M	0.0%	+28.8%	0.653%
2/14/2025	First Trust Advisors LP	2,700,125	$49.55M	0.0%	+27.0%	1.623%
2/13/2025	Canada Pension Plan Investment Board	780,700	$14.33M	0.0%	+19.9%	0.469%
2/13/2025	Marshall Wace LLP	993,593	$18.23M	0.0%	-16.4%	0.597%
2/13/2025	Jump Financial LLC	154,006	$2.83M	0.1%	-7.4%	0.093%
2/13/2025	Guggenheim Capital LLC	40,229	$0.74M	0.0%	-27.9%	0.024%
2/13/2025	Walleye Capital LLC	178,007	$3.27M	0.0%	+336.2%	0.107%
2/13/2025	Barclays PLC	298,445	$5.48M	0.0%	+7.5%	0.179%
2/13/2025	Summit Investment Advisors Inc.	12,519	$0.23M	0.2%	+6.8%	0.008%
2/13/2025	Rockefeller Capital Management L.P.	1,163,455	$21.35M	0.1%	+2.1%	0.699%
2/13/2025	Capital Fund Management S.A.	660,630	$12.12M	0.0%	-15.7%	0.397%
2/13/2025	F M Investments LLC	64,660	$1.19M	0.0%	N/A	0.039%
2/13/2025	Raymond James Financial Inc.	36,161	$0.66M	0.0%	N/A	0.022%
2/13/2025	Renaissance Technologies LLC	1,226,533	$22.51M	0.0%	+204.2%	0.737%
2/13/2025	Legal & General Group Plc	133,042	$2.44M	0.0%	-1.7%	0.080%
2/13/2025	Invesco Ltd.	512,320	$9.40M	0.0%	-8.2%	0.308%
2/13/2025	Bank of Montreal Can	11,522	$0.21M	0.0%	N/A	0.007%
2/13/2025	Cerity Partners LLC	20,459	$0.35M	0.0%	+43.2%	0.012%
2/13/2025	Aster Capital Management DIFC Ltd	40,609	$0.75M	0.3%	N/A	0.024%
2/13/2025	Russell Investments Group Ltd.	197,800	$3.63M	0.0%	-25.9%	0.119%
2/13/2025	Envestnet Asset Management Inc.	106,664	$1.96M	0.0%	-10.1%	0.064%
2/13/2025	Aviva PLC	35,883	$0.66M	0.0%	N/A	0.022%
2/13/2025	Wells Fargo & Company MN	202,349	$3.71M	0.0%	+7.7%	0.122%
2/12/2025	Uniting Wealth Partners LLC	11,000	$0.20M	0.1%	N/A	0.007%
2/12/2025	ExodusPoint Capital Management LP	70,786	$1.30M	0.0%	+20.2%	0.043%
2/12/2025	Arete Wealth Advisors LLC	13,700	$0.25M	0.0%	+15.9%	0.008%
2/12/2025	Massachusetts Financial Services Co. MA	59,283	$1.09M	0.0%	-2.9%	0.036%
2/12/2025	Trexquant Investment LP	433,155	$7.95M	0.1%	+12.8%	0.260%
2/12/2025	Headlands Technologies LLC	48,257	$0.89M	0.1%	+8.1%	0.029%

Data available starting January 2016

See Full Table

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.61

$16.28

$16.88

50 Day Range

MA: $18.34

$16.77

$20.37

52 Week Range

Now: $16.61

$14.15

$20.68

Volume

1,688,695 shs

Average Volume

1,822,785 shs

Market Capitalization

$2.77 billion

P/E Ratio

21.30

Dividend Yield

N/A

Beta

0.43

Who are the company insiders with the largest holdings of ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' top insider investors include:
Bros Advisors Lp Baker (Director)
Stephen Davis (CEO)
Brendan Teehan (COO)
Mark C Schneyer (EVP)
Mark C Schneyer (CFO)
Austin D Kim (EVP)
James Kihara (Insider)
Elizabeth A Garofalo (Director)
Laura Brege (Director)
Learn More about top insider investors at ACADIA Pharmaceuticals.
Who are the major institutional investors of ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' top institutional shareholders include:
Vanguard Group Inc. — 8.38%
RTW Investments LP — 5.23%
D. E. Shaw & Co. Inc. — 1.95%
Geode Capital Management LLC — 1.73%
Fred Alger Management LLC — 1.63%
First Trust Advisors LP — 1.62%
Learn More about top institutional investors of ACADIA Pharmaceuticals stock.
Which institutional investors are selling ACADIA Pharmaceuticals stock?: In the last quarter, ACAD stock was sold by these institutional investors:
RTW Investments LP
Millennium Management LLC
Balyasny Asset Management L.P.
Voloridge Investment Management LLC
Deutsche Bank AG
Fred Alger Management LLC
Squarepoint Ops LLC
Connor Clark & Lunn Investment Management Ltd.
During the previous year, company insiders that have sold ACADIA Pharmaceuticals company stock include:
Bros Advisors Lp Baker (Director)
Stephen Davis (CEO)
Brendan Teehan (COO)
Mark C Schneyer (EVP)
Mark C Schneyer (CFO)
Austin D Kim (EVP)
Learn More investors selling ACADIA Pharmaceuticals stock.
Which institutional investors are buying ACADIA Pharmaceuticals stock?: During the previous quarter, ACAD stock was purchased by institutional investors including:
Point72 Asset Management L.P.
SG Americas Securities LLC
Norges Bank
Renaissance Technologies LLC
Two Sigma Advisers LP
Cubist Systematic Strategies LLC
First Trust Advisors LP
Great Lakes Advisors LLC